Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013985 · ClinicalTrials.gov registry record · Phase 4
Glargine U300 Hospital Trial
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 247
- Enrollment target
NCT03013985 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 247 participants.
The verdict
NCT03013985, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 247 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
Interventions
- DRUG Glargine U300
- DRUG Glargine U100
- DRUG Glulisine Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03013985
The ClinicalTrials.gov registry entry for NCT03013985 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glargine U300 is the first listed.
NCT03013985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03013985 about?
NCT03013985 is a clinical study titled "Glargine U300 Hospital Trial". The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
What is the current status of trial NCT03013985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 247 participants. The study started on 2017-05-17. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03013985?
The interventions under investigation include: Glargine U300 (DRUG), Glargine U100 (DRUG), Glulisine Insulin (DRUG).
Who is sponsoring clinical trial NCT03013985?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.